EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Impact of atorvastatin reload on the prevention of contrast-induced nephropathy in patients on chronic statin therapy: A prospective randomized trial

Rania Hammami iD, Omar Masmoudi, Jihen Jdidi, Mouna Turki, Rim Charfi, Imtinene Ben Mrad, Amine Bahloul iD, Tarek Ellouze, Rania Gargouri, Samir Kammoun, Selma Charfeddine, Fatma Ayedi und 1 weitere

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0270000 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2023. Verfasst von Rania Hammami und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Hedi Chaker Hospital, University of Medicine, University of Sfax, Sfax, Tunisia. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Mellitus, Type 2, Percutaneous Coronary Intervention, Kidney Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This trial aimed to assess the efficacy of Atorvastatin reloading on the prevention of Contrast-induced nephropathy (CIN) in patients pre-treated with this statin and undergoing coronary catheterization.

Methods

This was a prospective randomized controlled study including patients on chronic atorvastatin therapy. We randomly assigned the population to the Atorvastatin Reloading group (AR group), by reloading patients with 80 mg of atorvastatin one day before and three days after the coronary procedure, and the Non-Reloading group (NR group), including patients who received their usual dose without a reloading dose. The primary endpoints were the incidence of cystatin (Cys)-based CIN and Creatinine (Scr)-based CIN. The secondary endpoints consisted of the changes in renal biomarkers (Δ biomarkers) defined as the difference between the follow-up level and the baseline level.

Results

Our population was assigned to the AR group (n = 56 patients) and NR group (n = 54 patients). The baseline characteristics of the 2 groups were similar. Serum creatinine (SCr)-based CIN occurred in 11.1% in the NR group, and in 8.9% in the AR group without any significant difference. Cys-based CIN occurred in 37% in the NR group and 26.8% in the AR group without any significant difference. The subgroup analysis showed that high dose reloading had significantly reduced the CYC-based CIN risk in patients with type 2 diabetes (43.5% vs 18.8%, RR = 0.43. CI 95% [0.18–0.99])). The comparison of “Δ Cystatin” and Δ eGFR between the AR and NR groups didn’t show any significant difference. However, cystatin C had significantly increased between baseline and at 24 hours in the NR group (0.96 vs 1.05, p = 0.001), but not in the AR group (0.94 vs 1.03, p = 0.206).

Conclusions

Our study did not find a benefit of systematic atorvastatin reloading in patients on chronic atorvastatin therapy in preventing CIN. However, it suggested that this strategy could reduce the risk of CyC-based CIN in diabetic type 2 patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsDiabetes Mellitus, Type 2Percutaneous Coronary InterventionKidney DiseasesHumansAtorvastatinProspective StudiesContrast MediaTreatment OutcomeBiomarkersCreatinineCoronary Angiography

Substanzen

AtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsContrast MediaBiomarkersCreatinine

Autor:innen und Institutionen

  • Cardiology Department, Hedi Chaker Hospital, University of Medicine, University of Sfax, Sfax, Tunisia.
  • Epidemiology Department, Hedi Chaker Hospital, University of Medicine, Sfax, Tunisia.
  • Biochemistry Department, Habib Bourguiba Hospital, University of Medicine, Sfax, Tunisia.
  • Cardiology Department Habib Thameur Hospital, Tunis, Tunisia.

ORCID-Profile: Rania Hammami, Amine Bahloul

Zitieren

APA

Hammami, R., Masmoudi, O., Jdidi, J., Turki, M., Charfi, R., Ben Mrad, I., Bahloul, A., Ellouze, T., Gargouri, R., Kammoun, S., Charfeddine, S., Ayedi, F., & Abid, L. (2023). Impact of atorvastatin reload on the prevention of contrast-induced nephropathy in patients on chronic statin therapy: A prospective randomized trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0270000

Vancouver

Hammami R, Masmoudi O, Jdidi J, Turki M, Charfi R, Ben Mrad I, et al. Impact of atorvastatin reload on the prevention of contrast-induced nephropathy in patients on chronic statin therapy: A prospective randomized trial. PLOS ONE. 2023. doi:10.1371/journal.pone.0270000

BibTeX
@article{Hammami2023,
  author = {Hammami, Rania and Masmoudi, Omar and Jdidi, Jihen and Turki, Mouna and Charfi, Rim and Ben Mrad, Imtinene and Bahloul, Amine and Ellouze, Tarek and Gargouri, Rania and Kammoun, Samir and Charfeddine, Selma and Ayedi, Fatma and Abid, Leila},
  title = {Impact of atorvastatin reload on the prevention of contrast-induced nephropathy in patients on chronic statin therapy: A prospective randomized trial},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0270000}
}
Kostenlos starten →